The study delves into the impact of rendering various World Health Organization (WHO) Expanded Program on Immunizations (EPI) vaccines thermostable within Niger’s vaccine supply chain. Through a comprehensive computational model, the research simulates the consequences of making different combinations of the six present EPI vaccines thermostable. The findings reveal that the thermostabilization of any EPI vaccine alleviates existing supply chain bottlenecks, particularly at lower levels, enhances vaccine availability across all EPI vaccines, and diminishes cold storage and transport capacity utilization. Notably, the most significant benefits are observed when the pentavalent vaccine is made thermostable, significantly boosting both its own availability and that of other non-thermostable EPI vaccines.
The study underscores the potential advantages of thermostablizing any of Niger’s EPI vaccines, emphasizing the need for further development in this arena. It highlights that beyond the mere elimination of refrigeration requirements, making even a single vaccine thermostable could substantially free up cold storage space for other vaccines, thereby addressing supply chain bottlenecks evident worldwide. The research reflects on the challenges posed by inadequate refrigeration methods in many regions, prompting the call for thermostable vaccines that can withstand various environmental conditions during transit through a country’s vaccine supply chain.
The results underscore the dynamic benefits that thermostable vaccines could offer not only to the distribution of the thermostabilized vaccine itself but also to all other vaccines within the supply chain. The study suggests that while the thermostabilization of larger vaccines like the pentavalent yields greater distribution benefits, a detailed computational model is essential to quantify the full scope of these effects accurately. By prioritizing the development of a thermostable pentavalent vaccine over other EPI vaccines, the research guides stakeholders on which vaccines to focus on, taking into account differential impacts on the vaccine supply chain.
Moreover, the study acknowledges the evolving landscape of vaccine thermostabilization efforts, with promising advancements in various formulations being explored. It emphasizes that while the technical feasibility and disease burden are crucial drivers for prioritizing vaccine thermostability research, the effects on the vaccine supply chain should also be considered to ensure effective vaccine dissemination. The research advocates for a holistic approach to vaccine development, combining thermostabilization with other supply chain enhancement measures to optimize performance. Additionally, the study’s findings are supported by a team of experts and funded by reputable organizations, ensuring the credibility and robustness of the research outcomes.
Tags: formulation
Read more on pmc.ncbi.nlm.nih.gov